Header Logo

Connection

Michelle Callegan to Animals

Back to Details
This is a "connection" page, showing publications Michelle Callegan has written about Animals.
Michelle Callegan
Connection Strength
2.151
Animals
  1. Contribution of Leukocidin ED to the Pathogenesis of Staphylococcus aureus Endophthalmitis. Invest Ophthalmol Vis Sci. 2025 May 01; 66(5):11.
    View in: PubMed
    Score: 0.089
  2. Novel Anti-Microbial/Anti-Inflammatory Combination Improves Clinical Outcome of Bacillus cereus Endophthalmitis. Invest Ophthalmol Vis Sci. 2025 Jan 02; 66(1):39.
    View in: PubMed
    Score: 0.087
  3. The Role of CCL Chemokines in Experimental Staphylococcus aureus Endophthalmitis. Invest Ophthalmol Vis Sci. 2024 Jun 03; 65(6):12.
    View in: PubMed
    Score: 0.084
  4. Virulence-related genotypic differences among Bacillus cereus ocular and gastrointestinal isolates and the relationship to endophthalmitis pathogenesis. Front Cell Infect Microbiol. 2023; 13:1304677.
    View in: PubMed
    Score: 0.081
  5. The Role of C-X-C Chemokines in Staphylococcus aureus Endophthalmitis. Invest Ophthalmol Vis Sci. 2023 Mar 01; 64(3):10.
    View in: PubMed
    Score: 0.077
  6. Roles of CCL2 and CCL3 in intraocular inflammation during Bacillus endophthalmitis. Exp Eye Res. 2022 11; 224:109213.
    View in: PubMed
    Score: 0.074
  7. C-X-C Chemokines Influence Intraocular Inflammation During Bacillus Endophthalmitis. Invest Ophthalmol Vis Sci. 2021 11 01; 62(14):14.
    View in: PubMed
    Score: 0.070
  8. Immune Inhibitor A Metalloproteases Contribute to Virulence in Bacillus Endophthalmitis. Infect Immun. 2021 09 16; 89(10):e0020121.
    View in: PubMed
    Score: 0.068
  9. The Bacillus virulome in endophthalmitis. Microbiology (Reading). 2021 05; 167(5).
    View in: PubMed
    Score: 0.068
  10. Intravitreal Injection and Quantitation of Infection Parameters in a Mouse Model of Bacterial Endophthalmitis. J Vis Exp. 2021 02 06; (168).
    View in: PubMed
    Score: 0.066
  11. Innate Immune Interference Attenuates Inflammation In Bacillus Endophthalmitis. Invest Ophthalmol Vis Sci. 2020 11 02; 61(13):17.
    View in: PubMed
    Score: 0.065
  12. Bacillus S-Layer-Mediated Innate Interactions During Endophthalmitis. Front Immunol. 2020; 11:215.
    View in: PubMed
    Score: 0.062
  13. S-layer Impacts the Virulence of Bacillus in Endophthalmitis. Invest Ophthalmol Vis Sci. 2019 09 03; 60(12):3727-3739.
    View in: PubMed
    Score: 0.060
  14. An Eye on Staphylococcus aureus Toxins: Roles in Ocular Damage and Inflammation. Toxins (Basel). 2019 06 19; 11(6).
    View in: PubMed
    Score: 0.059
  15. Targets of immunomodulation in bacterial endophthalmitis. Prog Retin Eye Res. 2019 11; 73:100763.
    View in: PubMed
    Score: 0.059
  16. Disarming Pore-Forming Toxins with Biomimetic Nanosponges in Intraocular Infections. mSphere. 2019 05 15; 4(3).
    View in: PubMed
    Score: 0.059
  17. TLR4 modulates inflammatory gene targets in the retina during Bacillus cereus endophthalmitis. BMC Ophthalmol. 2018 Apr 16; 18(1):96.
    View in: PubMed
    Score: 0.055
  18. The role of pili in Bacillus cereus intraocular infection. Exp Eye Res. 2017 06; 159:69-76.
    View in: PubMed
    Score: 0.051
  19. CXCL1, but not IL-6, significantly impacts intraocular inflammation during infection. J Leukoc Biol. 2016 11; 100(5):1125-1134.
    View in: PubMed
    Score: 0.048
  20. Bloodstream-To-Eye Infections Are Facilitated by Outer Blood-Retinal Barrier Dysfunction. PLoS One. 2016; 11(5):e0154560.
    View in: PubMed
    Score: 0.048
  21. Modeling intraocular bacterial infections. Prog Retin Eye Res. 2016 09; 54:30-48.
    View in: PubMed
    Score: 0.048
  22. Blood-Retinal Barrier Compromise and Endogenous Staphylococcus aureus Endophthalmitis. Invest Ophthalmol Vis Sci. 2015 Nov; 56(12):7303-11.
    View in: PubMed
    Score: 0.046
  23. Unexpected Roles for Toll-Like Receptor 4 and TRIF in Intraocular Infection with Gram-Positive Bacteria. Infect Immun. 2015 Oct; 83(10):3926-36.
    View in: PubMed
    Score: 0.045
  24. Role of TLR5 and flagella in bacillus intraocular infection. PLoS One. 2014; 9(6):e100543.
    View in: PubMed
    Score: 0.042
  25. TLR4 contributes to the host response to Klebsiella intraocular infection. Curr Eye Res. 2014 Aug; 39(8):790-802.
    View in: PubMed
    Score: 0.041
  26. The diabetic ocular environment facilitates the development of endogenous bacterial endophthalmitis. Invest Ophthalmol Vis Sci. 2012 Nov 01; 53(12):7426-31.
    View in: PubMed
    Score: 0.037
  27. Role of Toll-like receptor (TLR) 2 in experimental Bacillus cereus endophthalmitis. PLoS One. 2011; 6(12):e28619.
    View in: PubMed
    Score: 0.035
  28. Efficacy of vitrectomy in improving the outcome of Bacillus cereus endophthalmitis. Retina. 2011 Sep; 31(8):1518-24.
    View in: PubMed
    Score: 0.035
  29. Contribution of mucoviscosity-associated gene A (magA) to virulence in experimental Klebsiella pneumoniae endophthalmitis. Invest Ophthalmol Vis Sci. 2011 Aug 29; 52(9):6860-6.
    View in: PubMed
    Score: 0.035
  30. Bacillus cereus-induced permeability of the blood-ocular barrier during experimental endophthalmitis. Invest Ophthalmol Vis Sci. 2009 Aug; 50(8):3783-93.
    View in: PubMed
    Score: 0.029
  31. Hypermucoviscosity as a virulence factor in experimental Klebsiella pneumoniae endophthalmitis. Invest Ophthalmol Vis Sci. 2008 Nov; 49(11):4931-8.
    View in: PubMed
    Score: 0.028
  32. A role for tumor necrosis factor-alpha in experimental Bacillus cereus endophthalmitis pathogenesis. Invest Ophthalmol Vis Sci. 2008 Oct; 49(10):4482-9.
    View in: PubMed
    Score: 0.028
  33. Toward improving therapeutic regimens for Bacillus endophthalmitis. Invest Ophthalmol Vis Sci. 2008 Apr; 49(4):1480-7.
    View in: PubMed
    Score: 0.027
  34. Acute inflammation and loss of retinal architecture and function during experimental Bacillus endophthalmitis. Curr Eye Res. 2006 Nov; 31(11):955-65.
    View in: PubMed
    Score: 0.025
  35. Role of swarming migration in the pathogenesis of bacillus endophthalmitis. Invest Ophthalmol Vis Sci. 2006 Oct; 47(10):4461-7.
    View in: PubMed
    Score: 0.025
  36. Bacillus endophthalmitis: roles of bacterial toxins and motility during infection. Invest Ophthalmol Vis Sci. 2005 Sep; 46(9):3233-8.
    View in: PubMed
    Score: 0.023
  37. Relationship of plcR-regulated factors to Bacillus endophthalmitis virulence. Infect Immun. 2003 Jun; 71(6):3116-24.
    View in: PubMed
    Score: 0.020
  38. Contribution of membrane-damaging toxins to Bacillus endophthalmitis pathogenesis. Infect Immun. 2002 Oct; 70(10):5381-9.
    View in: PubMed
    Score: 0.019
  39. Bacterial endophthalmitis: epidemiology, therapeutics, and bacterium-host interactions. Clin Microbiol Rev. 2002 Jan; 15(1):111-24.
    View in: PubMed
    Score: 0.018
  40. Corticosteroid and antibiotic therapy for bacillus endophthalmitis. Arch Ophthalmol. 2001 Sep; 119(9):1391-3.
    View in: PubMed
    Score: 0.017
  41. T cell-intrinsic role for Nod2 in protection against Th17-mediated uveitis. Nat Commun. 2020 10 26; 11(1):5406.
    View in: PubMed
    Score: 0.016
  42. Kallistatin Attenuates Experimental Autoimmune Uveitis by Inhibiting Activation of T Cells. Front Immunol. 2020; 11:975.
    View in: PubMed
    Score: 0.016
  43. Ocular Glands Become Infected Secondarily to Infectious Keratitis and Play a Role in Corneal Resistance to Infection. J Virol. 2019 08 15; 93(16).
    View in: PubMed
    Score: 0.015
  44. Pathogenesis of gram-positive bacterial endophthalmitis. Infect Immun. 1999 Jul; 67(7):3348-56.
    View in: PubMed
    Score: 0.015
  45. Role of hemolysin BL in the pathogenesis of extraintestinal Bacillus cereus infection assessed in an endophthalmitis model. Infect Immun. 1999 Jul; 67(7):3357-66.
    View in: PubMed
    Score: 0.015
  46. Efficacy of tobramycin drops applied to collagen shields for experimental staphylococcal keratitis. Curr Eye Res. 1994 Dec; 13(12):875-8.
    View in: PubMed
    Score: 0.011
  47. Caveolin-1 increases proinflammatory chemoattractants and blood-retinal barrier breakdown but decreases leukocyte recruitment in inflammation. Invest Ophthalmol Vis Sci. 2014 Aug 26; 55(10):6224-34.
    View in: PubMed
    Score: 0.011
  48. Pharmacokinetic considerations in the treatment of bacterial keratitis. Clin Pharmacokinet. 1994 Aug; 27(2):129-49.
    View in: PubMed
    Score: 0.011
  49. Corneal virulence of Staphylococcus aureus: roles of alpha-toxin and protein A in pathogenesis. Infect Immun. 1994 Jun; 62(6):2478-82.
    View in: PubMed
    Score: 0.010
  50. Ciprofloxacin versus tobramycin for the treatment of staphylococcal keratitis. Invest Ophthalmol Vis Sci. 1994 Mar; 35(3):1033-7.
    View in: PubMed
    Score: 0.010
  51. Methicillin-resistant Staphylococcus aureus keratitis in the rabbit: therapy with ciprofloxacin, vancomycin and cefazolin. Curr Eye Res. 1992 Nov; 11(11):1111-9.
    View in: PubMed
    Score: 0.009
  52. Topical antibiotic therapy for the treatment of experimental Staphylococcus aureus keratitis. Invest Ophthalmol Vis Sci. 1992 Oct; 33(11):3017-23.
    View in: PubMed
    Score: 0.009
  53. Diabetes reduces autophosphorylation of retinal insulin receptor and increases protein-tyrosine phosphatase-1B activity. Invest Ophthalmol Vis Sci. 2009 Mar; 50(3):1033-40.
    View in: PubMed
    Score: 0.007
  54. The SAG1 Toxoplasma gondii surface protein is not required for acute ocular toxoplasmosis in mice. Infect Immun. 2007 Apr; 75(4):2079-83.
    View in: PubMed
    Score: 0.006
  55. Role of bacterial and host factors in infectious endophthalmitis. Chem Immunol Allergy. 2007; 92:266-275.
    View in: PubMed
    Score: 0.006
  56. Corneal expression of the inflammatory mediator CAP37. Invest Ophthalmol Vis Sci. 2002 May; 43(5):1414-21.
    View in: PubMed
    Score: 0.005
  57. Pseudomonas deficient in protease IV has significantly reduced corneal virulence. Invest Ophthalmol Vis Sci. 1997 Jul; 38(8):1535-42.
    View in: PubMed
    Score: 0.003
  58. Specific roles of alpha-toxin and beta-toxin during Staphylococcus aureus corneal infection. Infect Immun. 1997 May; 65(5):1571-8.
    View in: PubMed
    Score: 0.003
  59. Pseudomonas keratitis. The role of an uncharacterized exoprotein, protease IV, in corneal virulence. Invest Ophthalmol Vis Sci. 1996 Mar; 37(4):534-43.
    View in: PubMed
    Score: 0.003
  60. Pharmacokinetics of topically applied ciprofloxacin in rabbit tears. Jpn J Ophthalmol. 1996; 40(1):123-6.
    View in: PubMed
    Score: 0.003
  61. The effectiveness of two ciprofloxacin formulations for experimental Pseudomonas and Staphylococcus keratitis. Jpn J Ophthalmol. 1996; 40(2):212-9.
    View in: PubMed
    Score: 0.003
  62. Growth and virulence of a complement-activation-negative mutant of Streptococcus pneumoniae in the rabbit cornea. Curr Eye Res. 1995 Apr; 14(4):281-4.
    View in: PubMed
    Score: 0.003
  63. Effectiveness of specific antibiotic/steroid combinations for therapy of experimental Pseudomonas aeruginosa keratitis. Curr Eye Res. 1995 Mar; 14(3):229-34.
    View in: PubMed
    Score: 0.003
  64. Pseudomonas aeruginosa keratitis in leukopenic rabbits. Curr Eye Res. 1993 May; 12(5):461-7.
    View in: PubMed
    Score: 0.002
  65. Prednisolone acetate or prednisolone phosphate concurrently administered with ciprofloxacin for the therapy of experimental Pseudomonas aeruginosa keratitis. Curr Eye Res. 1993 May; 12(5):469-73.
    View in: PubMed
    Score: 0.002
  66. Bioassays for quantitating ciprofloxacin and tobramycin in aqueous humor. J Ocul Pharmacol. 1993; 9(4):311-20.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.